文献速递心血管US

超声空化技术治疗肥厚型心肌病:原理验证

Ultrasonic Cavitation-Enabled Treatment for Therapy of Hypertrophic Cardiomyopathy: Proof of Principle.
PubMed 文献 · Ultrasound Med Biol · 2018-04-19

在SS-16BN大鼠肥厚型心肌病模型中,以10 MHz成像引导聚焦超声联合微泡行心肌空化治疗,28天后靶向室壁厚度较假手术组降低16.2%(p<0.01),心肌应变率和心内膜位移分别降低34%和29%,提示该无创方法有望成为肥厚型心肌病新治疗选择。

要点

  • 超声心肌空化治疗在肥厚型心肌病大鼠模型中使靶向室壁厚度较假手术组降低16.2%(p<0.01)。
  • 治疗后心肌应变率降低34%、心内膜位移降低29%,达到治疗所需效应。
  • 室性早搏与血浆肌钙蛋白测定可识别最佳与次佳治疗队列。

核心结论

  • 超声心肌空化治疗在SS-16BN大鼠肥厚型心肌病模型中验证了心肌减容治疗的原理,并显著降低靶向室壁厚度。

研究设计与样本

  • 在SS-16BN大鼠肥厚型心肌病模型中进行原理验证研究。
  • 使用10 MHz成像(10 S,GE Vivid 7)引导聚焦超声换能器,靶向麻醉大鼠左心室壁,大鼠置于温水浴中。

关键影像表现/征象

  • 以4 MPa峰值负压脉冲群间歇触发,每8个心动周期触发1次,在10分钟微气泡悬液输注期间进行。
  • 治疗28天后,靶向室壁厚度较假手术组降低16.2%(p<0.01),心肌应变率和心内膜位移分别降低34%和29%。
  • 室性早搏与血浆肌钙蛋白测量可识别最佳与次佳治疗队列。

临床应用与阅片要点

  • 治疗期间给予甲泼尼龙以减轻初期炎症,并给予氯沙坦以减少愈合组织纤维化。
  • 室性早搏和血浆肌钙蛋白测量有助于识别最佳与次佳治疗队列。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Ultrasound myocardial cavitation-enabled treatment was applied to the SS-16BN rat model of hypertrophic cardiomyopathy for proof of the principle underlying myocardial reduction therapy. A focused ultrasound transducer was targeted using 10-MHz imaging (10 S, GE Vivid 7) to the left ventricular wall of anesthetized rats in a warmed water bath. Pulse bursts of 4-MPa peak rarefactional pressure amplitude were intermittently triggered 1:8 heartbeats during a 10-min infusion of a microbubble suspension. Methylprednisolone was given to reduce initial inflammation, and Losartan was given to reduce fibrosis in the healing tissue. At 28 d post therapy, myocardial cavitation-enabled treatment significantly reduced the targeted wall thickness by 16.2% (p <0.01) relative to shams, with myocardial strain rate and endocardial displacement reduced by 34% and 29%, respectively, which are sufficient for therapeutic treatment. Premature electrocardiogram complexes and plasma troponin measurements were found to identify optimal and suboptimal treatment cohorts and would aid in achieving the desired impact. With clinical translation, myocardial cavitation-enabled treatment should fill the need for a new non-invasive hypertrophic cardiomyopathy therapy option.

来源:Ultrasound Med Biol,查看原文。版权归原作者所有。

引用

  1. Miller DL, Lu X, Dou C, et al. Ultrasonic Cavitation-Enabled Treatment for Therapy of Hypertrophic Cardiomyopathy: Proof of Principle. Ultrasound Med Biol. 2018. PMID: 29681423. doi:10.1016/j.ultrasmedbio.2018.03.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。